Could cooling the body save hearts after a massive attack?
NCT ID NCT07186972
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests if gently cooling the body (to 33-34°C) during emergency heart procedures can limit heart damage in people having a severe heart attack complicated by shock. All 44 participants will receive standard care with a heart-lung machine, and half will also be cooled for 24 hours. Researchers will measure heart muscle recovery and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mild therapeutic hypothermia (controlled cooling of the body)
- What this could lead to
- If it works, this cooling method could reduce heart muscle damage and improve survival for people having a severe heart attack with shock.
- What could go wrong
- This is a small, early trial with only 44 people, so results may not apply to everyone. Cooling carries risks like infection or irregular heartbeat.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients diagnosed with acute myocardial infarction complicated by cardiogenic shock who undergo emergency percutaneous coronary intervention under venoarterial extracorporeal membrane oxygenation support and endotracheal intubation. 2. Patients diagnosed with anterior wall myocardial infarction. 3. Aged ≥18 years. Exclusion Criteria: 1. Cardiogenic shock lasting more than 12 hours or a history of chronic congestive heart failure. 2. History of prior coronary artery intervention, coronary artery bypass grafting, heart transplantation, heart-lung transplantation, or left ventricular assist device implantation. 3. Cardiogenic shock associated with mechanical complications of acute myocardial infarction, such as ventricular septal rupture, acute mitral regurgitation, acute ventricular septal defect, and cardiac tamponade. 4. Refractory out-of-hospital cardiac arrest or cardiopulmonary resuscitation lasting longer than 45 minutes. 5. Known end-stage renal disease (e.g., on dialysis or post-kidney transplantation) or severe liver failure (e.g., cirrhosis or acute hepatitis). 6. Contraindications to hypothermia therapy, such as cryoglobulinemia, sickle cell disease, cold agglutinin disease, and vasospastic disorders (e.g., Raynaud's disease and thromboangiitis obliterans). 7. Refusal to undergo 99mTc-sestamibi single photon emission tomography imaging or presence of known or suspected contraindications to 99mTc-sestamibi single photon emission tomography imaging. 8. Pregnency. 9. Currently participation in other interventional clinical trials. 10. Refusal to sign informed consent related to this trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction complicated with cardiogenic shock are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.